GENFIT: 2021 Financial Calendar

Lille, France; Cambridge, MA; February 10, 2021 – GENFIT (Nasdaq and Euronext: GNFT), a late-stage biopharmaceutical company dedicated to improving the lives of patients with metabolic and liver diseases, today announced its provisional financial calendar for 2021. February 26, 2021:                              Publication of revenue and cash position at December 31, 2020 April 1, 2021:                                       Publication… Continue reading GENFIT: 2021 Financial Calendar

GENFIT: 2021 Financial Calendar

Lille, France; Cambridge, MA; February 10, 2021 – GENFIT (Nasdaq and Euronext: GNFT), a late-stage biopharmaceutical company dedicated to improving the lives of patients with metabolic and liver diseases, today announced its provisional financial calendar for 2021. February 26, 2021:                              Publication of revenue and cash position at December 31, 2020 April 1, 2021:                                       Publication… Continue reading GENFIT: 2021 Financial Calendar

GENFIT Announces Publication of Positive Results from the Phase 2 Clinical Trial Evaluating Elafibranor in Patients with PBC in the Journal of Hepatology

Lille, France; Cambridge, MA; February 09, 2021 – GENFIT (Nasdaq and Euronext: GNFT), a late-stage biopharmaceutical company dedicated to improving the lives of patients with metabolic and liver diseases, today announced that the positive results from the Phase 2 clinical trial evaluating elafibranor in patients with Primary Biliary Cholangitis (PBC) with incomplete response to ursodeoxycholic… Continue reading GENFIT Announces Publication of Positive Results from the Phase 2 Clinical Trial Evaluating Elafibranor in Patients with PBC in the Journal of Hepatology

GENFIT announces that its Extraordinary General Meeting on second notice will be held January 25, 2021 and informs the OCEANEs holders of certain procedures for the Bondholders’ Meeting of January 25, 2021

Lille, France; Cambridge, MA; January 13, 2021 – GENFIT (Nasdaq and Euronext: GNFT), a late-stage biopharmaceutical company dedicated to improving the lives of patients with metabolic and liver diseases (the “Company”), today announces the publication in the January 13, 2021 French Bulletin des Annonces Légales Obligatoires of its convening notice for the shareholders’ extraordinary general… Continue reading GENFIT announces that its Extraordinary General Meeting on second notice will be held January 25, 2021 and informs the OCEANEs holders of certain procedures for the Bondholders’ Meeting of January 25, 2021

GENFIT announces that its Extraordinary General Meeting on second notice will be held January 25, 2021 and informs the OCEANEs holders of certain procedures for the Bondholders’ Meeting of January 25, 2021

Lille, France; Cambridge, MA; January 13, 2021 – GENFIT (Nasdaq and Euronext: GNFT), a late-stage biopharmaceutical company dedicated to improving the lives of patients with metabolic and liver diseases (the “Company”), today announces the publication in the January 13, 2021 French Bulletin des Annonces Légales Obligatoires of its convening notice for the shareholders’ extraordinary general… Continue reading GENFIT announces that its Extraordinary General Meeting on second notice will be held January 25, 2021 and informs the OCEANEs holders of certain procedures for the Bondholders’ Meeting of January 25, 2021

GENFIT announces that its Extraordinary General Meeting on second notice will be held January 25, 2021 and informs the OCEANEs holders of certain procedures for the Bondholders’ Meeting of January 25, 2021

Lille, France; Cambridge, MA; January 13, 2021 – GENFIT (Nasdaq and Euronext: GNFT), a late-stage biopharmaceutical company dedicated to improving the lives of patients with metabolic and liver diseases (the “Company”), today announces the publication in the January 13, 2021 French Bulletin des Annonces Légales Obligatoires of its convening notice for the shareholders’ extraordinary general… Continue reading GENFIT announces that its Extraordinary General Meeting on second notice will be held January 25, 2021 and informs the OCEANEs holders of certain procedures for the Bondholders’ Meeting of January 25, 2021

January 13, 2021 Extraordinary Shareholders Meeting: Wide support for the resolutions submitted to the shareholders’ vote but quorum not met on first convening

Partial buyback and amendment of the bond terms approved by approx. 98% of voting shareholders at this time Insufficient quorum of 20.63% on first convening, but greater than the 20% quorum required on second convening Extraordinary Shareholders Meeting will be reconvened on January 25, 2021 with the same agenda Votes cast on the first convening… Continue reading January 13, 2021 Extraordinary Shareholders Meeting: Wide support for the resolutions submitted to the shareholders’ vote but quorum not met on first convening

GENFIT: Half-Year Report of Liquidity Contract with Crédit Industriel et Commercial

Lille, France; Cambridge, MA; January 11, 2021 – GENFIT (Nasdaq and Euronext: GNFT), a late-stage biopharmaceutical company dedicated to improving the lives of patients with metabolic and liver diseases, today announced the half-year report of the liquidity contract with Crédit Industriel et Commercial. Under the liquidity contract GENFIT has with Crédit Industriel et Commercial, the… Continue reading GENFIT: Half-Year Report of Liquidity Contract with Crédit Industriel et Commercial